Prolactinomas Apparently Resistant to Quinagolide Respond to Cabergoline Therapyc

Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.

BACKGROUND Dopamine agonist resistance in prolactinoma is an infrequent phenomenon. Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (PRL) secretion and reducing tumor size in prolactinomas. The clinical presentation, management, and outcome of patients that are not well controlled by such commonly used doses of CAB-resistant patients are poorly und...

Valvular Heart Disease in Patients with Prolactinomas on Cabergoline Treatment

Dopamine agonists are the first line treatment of prolactinomas and Parkinson’s disease. Has shown an association between the use of high doses of ergot dopamine agonists, cabergoline and pergolide, and development of clinically significant (moderate to severe) heart valve regurgitation, valvular thickening and retraction in patients with Parkinson’s disease [1,2]. Because of this, he has appea...

A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology

Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment ...

Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.

INTRODUCTION Hyperprolactinemia and hypogonadism are reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of testosterone replacement and cabergoline (CAB) treatment on the metabolic profile in male hyperprolactinemic patients. PATIENTS AND METHODS Thirty-two men with prolactinomas, including 22 with total testosterone (TT) <8 nmol/l (...

World must respond to threat of drug-resistant tuberculosis.